5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
ISSN
14702045
Date Issued
2016
Author(s)
DOI
10.1016/S1470-2045(16)00163-7
Subjects